Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-13), Paradigm Biopharmaceuticals's 3-1 Month Momentum % is 23.53%.
The industry rank for Paradigm Biopharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:
STU:P86's 3-1 Month Momentum % is ranked better than 80.84% of 1378
companies
in the Biotechnology industry
Industry Median: 1.51
vs STU:P86: 23.53
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Paradigm Biopharmaceuticals 3-1 Month Momentum % Related Terms
STU:P86 vs VRTX, REGN, MRNA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Paradigm Biopharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paradigm Biopharmaceuticals 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Paradigm Biopharmaceuticals's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paradigm Biopharmaceuticals (STU:P86) has a 3-1 Month Momentum % of 23.53% as of Sep. 13, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Paradigm Biopharmaceuticals and its competitors. According to the industry distribution chart, Paradigm Biopharmaceuticals ranks #264 out of 1378 companies in the Biotechnology industry, placing it in the top 19.2%.
Is Paradigm Biopharmaceuticals' 3-1 Month Momentum % too high?
Paradigm Biopharmaceuticals' current 3-1 Month Momentum % is 23.53%. The Biotechnology industry median 3-1 Month Momentum % is 1.51. Paradigm Biopharmaceuticals' value of 23.53% is 1458.3% above this industry median. Based on the distribution chart, Paradigm Biopharmaceuticals ranks #264 out of 1378 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Paradigm Biopharmaceuticals ranks #264 out of 1378 companies for 3-1 Month Momentum %. This places Paradigm Biopharmaceuticals in the top 19% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 1.51. Paradigm Biopharmaceuticals' value of 23.53% is 1458.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 1.51, based on 1,378 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paradigm Biopharmaceuticals's current 3-1 Month Momentum % of 23.53% is 1458.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Paradigm Biopharmaceuticals and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 1.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paradigm Biopharmaceuticals's current 3-1 Month Momentum % is 23.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (STU:P86) has a current 3-1 Month Momentum % of 23.53%. The current 3-1 Month Momentum % is 23.53% and 1458.3% above the Biotechnology industry median of 1.51. Paradigm Biopharmaceuticals' overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (STU:P86), the current 3-1 Month Momentum % is 23.53% as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
12GF Score
Get the complete analysis for STU:P86
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:P86 has been successfully added to your 
